US5324571083 - Common Stock
598.05 +9.78 (+1.66%)
After market: 599.3 +1.25 (+0.21%)
These stocks could be just the ticket for investors seeking strong growth.
The latest trading day saw Eli Lilly (LLY) settling at $598.05, representing a +1.66% change from its previous close.
Zepbound has a much lower sticker price than its rival, Novo Nordisk's Wegovy
Eli Lilly (LLY) declares $1.30/share quarterly dividend, 15% increase from prior dividend of $1.13. Forward yield 0.89% Payable March 8; for shareholders of rec
/PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for...
These drugs address a rapidly growing market.
The S&P 500 is performing well thanks largely to the Magnificent 7. Here are three companies whose stocks could soon join the exclusive club.
Get an extensive Neuropsychiatric Disorders And Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Eli Lilly's breast cancer drug, Verzenio, receives label expansion authorization in Canada, offering treatment options for a broader range of patients at...
Which of these top-performing growth funds is the better buy?
Eli Lilly's P/E ratio of more than 100 looks steep, but the company is on the cusp of further huge growth.
There's no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has a clear edge.
CNBC's Jim Cramer pointed out investors' mistakes when evaluating mega cap stocks on Tuesday.
Shares in Eli Lilly are up around 60% year-to-date, while Novo Nordisk has gained around 50%. Should investors buy either stock — or both?
Eli Lilly's (LLY) acquisition of radiopharmaceutical company POINT Biopharma (PNT) is facing challenges as investors show lack of interest. Read more here.
Eli Lilly&#39;s (LLY) acquisition of radiopharmaceutical company POINT Biopharma (PNT) is facing challenges as investors show lack of interest. Read more here.
Eli Lilly's drug serves as an alternative to rival obesity drugs such as Wegovy that are still facing supply issues.
Law firms are seeking to consolidate lawsuits related to side effects of GLP-1 class of drugs filed against Novo Nordisk (NVO) and Eli Lilly (LLY). Read more here.
The Human Made and Kenzo designer talks about Virgil Abloh, Bape and what it’s like to work for the world’s biggest luxury company.
Saudi Arabia cut its official crude oil selling prices to Asia next month amid a continued supply glut, a sign of weakness in markets as OPEC and its allies deepen production cuts in an attempt to avoid a surplus.
A swath of Norway’s offshore gas discoveries risk remaining untapped due to challenges ranging from complex reservoirs to costs of production.
Entain Plc. will pay £615 million ($777 million) to resolve a probe with UK prosecutors following an investigation into potential bribery offenses at its former Turkish business.
Eli Lilly & Co.’s new weight-loss drug Zepbound is now available at US pharmacies, offering an alternative to rival medications like Novo Nordisk A/S’s Wegovy as supply issues persist.
Without any insurance coverage, a monthly dose of Eli Lilly and Company's GLP-1 weight loss drug is priced at $1,060 in the US.
Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with...
The company is making the weight-loss drug accessible to adults through its commercial savings card program, where people who are commercially insured with coverage may be eligible to pay as low as $25 for a 1-month or 3-month prescription. The drug was approved in November, paving the way for a powerful new rival to Novo Nordisk's Wegovy in addressing record obesity rates. Lilly's drug tirzepatide has been available as Mounjaro for type 2 diabetes since 2022 and had increasingly been used "off-label" for weight loss while the obesity approval was pending.
Eli Lilly's recently approved obesity drug Zepbound is now available in U.S. pharmacies and could be available to some insured customers at $550 per month or half of the list price, the U.S. drugmaker said on Tuesday. The company is making the weight-loss drug accessible to adults through its commercial savings card program, where people who are commercially insured with coverage may be eligible to pay as low as $25 for a 1-month or 3-month prescription. The drug was approved in November, paving the way for a powerful new rival to Novo Nordisk's Wegovy in addressing record obesity rates.
Eli Lilly & Co. said Tuesday its new obesity drug Zepbound has been added to a major pharmacy benefit manager’s preferred formulary, or list of covered...
Eli Lilly's weight loss drug Zepbound (tirzepatide) is now available nationwide, offering potential savings for commercially insured patients.
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available. Zepbound is indicated for adults...
Bristol Myers Squibb's combination therapy for urothelial carcinoma receives priority review from the FDA, potentially offering a new treatment option in...
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.